Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

Phase 3

Completed

• Conditions: Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

• Registration Number: NCT00338260
• Lead Sponsor: Organon and Co

Brief Summary

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Detailed Description

Not available

Study Timeline

• Study Start: 1995-06
• Primary Completion: 2001-09
• Study Completion: 2001-11
• Study First Submitted: 2006-06-15
• Study First Submitted QC: 2006-06-15
• Study First Posted: 2006-06-20
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-07
• Last Update Posted: 2022-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 496

Inclusion Criteria

• Age 55 to 80 years
• Males and females
• Hypertension (160-200/95-115 mm Hg
• ECG evidence of left ventricular hypertrophy

Exclusion Criteria

• Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
• Myocardial infarction or stroke within 6 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

Secondary Outcome Measures

Name	Time	Method
cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus